Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537463 | 0.83 | RORC (0.50) | DRD4TMEM97SIGMAR1LTA4HDRD2 | |
| SCHEMBL537037 | 0.80 | DRD2 (0.48) | DRD4TMEM97SIGMAR1LTA4HCYP1A2 | |
| SCHEMBL2602802 | 0.78 | GAA (0.52) | DRD4LTA4HCYP2C9DRD2DRD3 | |
| SCHEMBL2602796 | 0.76 | DRD4 (0.43) | DRD4TMEM97SIGMAR1LTA4HCYP1A2 | |
| SCHEMBL537357 | 0.75 | SLC2A1 (0.42) | DRD4TMEM97SIGMAR1LTA4HCYP3A4 | |
| SCHEMBL537468 | 0.75 | DRD4 (0.41) | DRD4TMEM97SIGMAR1LTA4HCYP1A2 | |
| SCHEMBL6132849 | 0.73 | DRD4 (0.51) | DRD4SIGMAR1LTA4HCYP1A2CYP3A4 | |
| SCHEMBL13597304 | 0.73 | ACHE (0.54) | DRD4SIGMAR1CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6261135 | 0.71 | SIGMAR1 (0.68) | DRD4SIGMAR1HRH3 | |
| SCHEMBL13597305 | 0.70 | DRD4 (0.49) | DRD4SIGMAR1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | PSEN1, MAPT, PSEN2 | DRD4 1511/4885TMEM97 2699/4885SIGMAR1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.